Oxygenation and ventilation parameters in children with Prader-Willi syndrome without or with growth hormone treatment.

<bold>Introduction:</bold> Prader-Willi syndrome (PWS) is characterized by muscle hypotonia, obesity, and hypothalamic dysfunction predisposing to OSAS and hypoventilation. Growth hormone (GH) is an approved treatment with potential favorable effects on oxygenation and ventilation during sleep. <bold>Aims:</bold> To compare children with PWS who were or were not receiving GH regarding oxycapnography parameters. <bold>Methods:</bold> Retrospective (June 2013-April 2023) analysis of most recent oxycapnography data. <bold>Results:</bold> 17 patients with PWS were studied: 5 were on GH (age range 2.3-14.7 y; median BMI-z 1.5, range 0.7-3.1; group 1); 8 were studied prior to GH (age 1.3-13.3 y; BMI-z 2.5, 1-3.99; group 2); and 4 were on NIV without GH (8.1-17.1 y; BMI-z 2.8, 2.6-3.1; group 3). Group 1 had no significant difference in ODI3, McGill oximetry score (MOS), %recording time with ETCO2>50 compared to group 2: ODI3 5.9/h (2.6-16/h) vs 10/h (3.3-47/h) (P=0.19); MOS 1 (1-4) vs 1 (1-2)(P=0.37) and %recording time with ETCO2>50 0% (0-0%) vs 0 (0.06-16.8%) (P=0.52). The two groups were similar in BMI-z (P=0.29). <bold>Conclusions:</bold> Children with PWS and with or without GH treatment did not differ in oxycapnography parameters or the degree of adiposity.